Stock Warrant
WARRANTPasithea Therapeutics Corp. Warrants
No redemption notice detected. Our weekly 8-K watcher runs every Friday and stamps this card if the issuer files a redemption 8-K.
KTTAW is Pasithea Therapeutics Corp. (Healthcare) — a non-dividend-paying stock. Trading at $0.01. Capital Quality Rank: 43/100 — Stagnant mediocrity.
Stock snapshot
| Price | $0.01 |
| Market cap | — |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 43 / 100 · Stagnant mediocrity |
| ROIC (TTM) | -16869.6% |
| Shareholder buyback yield | 0.00% |
| Altman Z-score zone | Distress |
About KTTAW
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Related non-dividend companies
Other non-dividend stocks investors research alongside KTTAW. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is KTTAW's current stock price?
KTTAW (Pasithea Therapeutics Corp.) is currently trading at $0.01.
Does KTTAW pay a dividend?
KTTAW (Pasithea Therapeutics Corp.) does not currently pay a regular dividend.
What is KTTAW's Capital Quality Rank?
KTTAW has a Capital Quality Rank of 43/100 — Stagnant mediocrity. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track KTTAW in DiviDrip
Add KTTAW to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search KTTAW and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-08-30. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.